The next obesity-drug race is about access and durability

What happened

Developers and health systems are looking beyond headline efficacy toward manufacturing capacity, tolerability, long-term adherence, and the total cost of care.

Why it matters

A therapy that works in a trial but is difficult to supply or sustain will have limited population impact. Delivery and affordability are now part of the clinical story.